IART
HealthcareIntegra LifeSciences Holdings Corporation
Key Drivers
- Margin Recovery
- Strong Liquidity
- Heavy Debt
AIAI Summary
IART is an execution-driven turnaround, not a cheap-value play: upside depends on sustaining margin and free-cash-flow recovery while reducing its $2.05B debt load, with SurgiMend's Q4 2026 relaunch a key proof point; avoid treating a single strong quarter as confirmation until deleveraging and supply reliability are visible.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Recovery
- •Strong Liquidity
- •Heavy Debt
IART is recovering operationally with improved margins, profit, cash flow and liquidity, but high debt, weak interest coverage and fragile earnings keep the risk profile elevated.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support test
- •Oversold rebound
IART remains in a last-month downtrend below $15.51, with a potential oversold bounce from $15.10 support but no reversal confirmation unless it clears $15.50–$15.70.
Modest rebound to $15.22 after sustained selling pressure
Sentiment & News
Key News Insights:
- •Q2 Margin Expansion
- •Debt Reduction Plan
- •FDA Recovery Catalysts
Integra LifeSciences' turnaround case is supported by stronger Q2 results, margin expansion and debt-reduction plans, but remains contingent on FDA approvals, customer recovery and improved tissue-reconstruction execution.
The news is cautiously positive for IART, though leverage and execution risks may limit near-term upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings